T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
926
lululemon athletica
LULU
$13.6B
| $34M | ﹤0.01% |
163,418
-2,134
| -1% | -$387K |
|
927
Arcutis Biotherapeutics
ARQT
$3.25B
| $33.9M | ﹤0.01% |
1,166,348
+1,078,546
| +1,228% | +$27.6M |
|
928
AZZ Inc
AZZ
$4.52B
| $33.8M | ﹤0.01% |
315,485
+282,676
| +862% | +$29.3M |
|
929
Lennar Class A
LEN
$21.1B
| $33.6M | ﹤0.01% |
327,267
-16,792
| -5% | -$2.03M |
|
930
Immunocore
IMCR
$1.74B
| $33.6M | ﹤0.01% |
968,784
-47,987
| -5% | -$1.69M |
|
931
Power Integrations
POWI
$3.48B
| $33.5M | ﹤0.01% |
943,365
+895,857
| +1,886% | +$34M |
|
932
Grupo Aeroportuario del Sureste
ASR
$8.01B
| $33.4M | ﹤0.01% |
103,379
+2,134
| +2% | +$660K |
|
933
Edison International
EIX
$27.2B
| $33.2M | ﹤0.01% |
552,883
-4,587
| -0.8% | -$263K |
|
934
StoneCo
STNE
$2.49B
| $33.1M | ﹤0.01% |
2,239,977
+75,434
| +3% | +$1.26M |
|
935
Globalstar
GSAT
$10.7B
| $33M | ﹤0.01% |
539,817
+157,443
| +41% | +$8.69M |
|
936
B2Gold
BTG
$6.7B
| $32.9M | ﹤0.01% |
+7,294,502
| New | +$34M |
|
937
Cirrus Logic
CRUS
$6.08B
| $32.8M | ﹤0.01% |
276,554
-141,769
| -34% | -$17.5M |
|
938
Kodiak Sciences
KOD
$2.5B
| $32.7M | ﹤0.01% |
1,170,179
+667,957
| +133% | +$13.7M |
|
939
Zebra Technologies
ZBRA
$18B
| $32.5M | ﹤0.01% |
133,650
-71,054
| -35% | -$19M |
|
940
Everest Group
EG
$14B
| $32.2M | ﹤0.01% |
95,016
-6,839
| -7% | -$2.26M |
|
941
T. Rowe Price
TROW
$23.7B
| $32.1M | ﹤0.01% |
313,922
+574
| +0.2% | +$59.2K |
|
942
Grab
GRAB
$15.1B
| $32.1M | ﹤0.01% |
6,424,434
+5,301,125
| +472% | +$29.3M |
|
943
Brinker International
EAT
$10.2B
| $31.7M | ﹤0.01% |
220,895
+1,493
| +0.7% | +$196K |
|
944
Cabot Corp
CBT
$4.45B
| $31.6M | ﹤0.01% |
476,672
+1,434
| +0.3% | +$95.5K |
|
|
BETA
945
Beta Technologies Inc
BETA
$6.14B
| $31.5M | ﹤0.01% |
+1,116,995
| New | +$33.3M |
|
946
GXO Logistics
GXO
$5.56B
| $31M | ﹤0.01% |
589,274
-11,915
| -2% | -$626K |
|
947
Service Corp International
SCI
$11.3B
| $30.9M | ﹤0.01% |
395,678
-1,572
| -0.4% | -$126K |
|
948
Axcelis
ACLS
$4.42B
| $30.8M | ﹤0.01% |
383,056
-149,052
| -28% | -$12.5M |
|
949
HP
HPQ
$28.6B
| $30.8M | ﹤0.01% |
1,380,738
-217,682
| -14% | -$5.55M |
|
|
ARES.PRB
950
Ares Management Corp 6.75% Series B Preferred Stock
ARES.PRB
$1.41B
| – | – |
0
| – | – |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.